Clinical Features of Patients with Systemic Sclerosis Positive for Anti-SS-A Antibody: a Cohort Study of 156 Patients

Overview

Journal Arthritis Res Ther

Publisher Biomed Central

Specialty Rheumatology

Date 2024 May 3

PMID 38702799

Authors

Tomoya Watanabe

Yasushi Ototake

Asami Akita

Mao Suzuki

Miwa Kanaoka

Jun Tamura

Yusuke Saigusa

Yukie Yamaguchi

Affiliations

Soon will be listed here.

Abstract

Background: Anti-SS-A/Ro antibody (anti-SSA), the diagnostic marker of Sjögren's syndrome (SS), is often detected in systemic sclerosis (SSc). Some patients are diagnosed with SSc/SS overlap syndromes, while there are anti-SSA-positive SSc cases without SS. In this study, we investigated the clinical characteristics of SSc with anti-SSA and clarified the clinical impact of this antibody in SSc.

Methods: A retrospective chart review was conducted of 156 patients with SSc at Yokohama City University Hospital from 2018 to 2021. Clinical data, laboratory data, imaging, and autoantibody positivity status were collected and analysed to assess the association between these variables and anti-SSA using multivariable logistic regression analysis.

Results: This cohort included 18 men and 138 women with SSc (median age, 69.0 years). Thirty-nine patients had diffuse cutaneous SSc (dcSSc) (25%), and 117 patients had limited cutaneous SSc (75%). Forty-four patients were anti-SSA-positive. Among them, 24 fulfilled the SS criteria. Multivariable logistic regression revealed that anti-SSA was statistically associated with interstitial lung disease (ILD; odds ratio [OR] = 2.67; 95% confidence interval [CI], 1.14-6.3; P = 0.024). Meanwhile, anti-SSA positivity tended to increase the development of digital ulcer (OR = 2.18; 95% CI, 0.99-4.82, P = 0.054). In the comparative analysis of the autoantibody single-positive and anti-SSA/SSc-specific autoantibody double-positive groups, the anti-SSA single-positive group showed a significantly increased risk of ILD (OR = 12.1; 95% CI, 2.13-140.57; P = 0.003). Furthermore, patients with SSc and anti-SSA indicated that anti-SSA-positive SSc without SS was strongly associated with dcSSc when compared to that in patients with SS (OR = 6.45; 95% CI, 1.23-32.60; P = 0.024).

Conclusions: Anti-SSA positivity increases the risk of organ involvement, such as ILD, in patients with SSc. Additionally, the anti-SSA-positive SSc without SS population may have more severe skin fibrosis than others. Anti-SSA may be a potential marker of ILD and skin severity in SSc.

Citing Articles

A Review of the Impact of Sjögren's Syndrome and/or the Presence of Anti-Ro/SS-A Antibodies on Therapeutic Strategies for Rheumatoid Arthritis.

Horai Y, Kurushima S, Shimizu T, Nakamura H, Kawakami A J Clin Med. 2025; 14(2).

PMID: 39860574 PMC: 11766391. DOI: 10.3390/jcm14020568.

References

Chan E, Hamel J, Buyon J, Tan E . Molecular definition and sequence motifs of the 52-kD component of human SS-A/Ro autoantigen. J Clin Invest. 1991; 87(1):68-76. PMC: 294993. DOI: 10.1172/JCI115003. View

Espinosa A, Dardalhon V, Brauner S, Ambrosi A, Higgs R, Quintana F . Loss of the lupus autoantigen Ro52/Trim21 induces tissue inflammation and systemic autoimmunity by disregulating the IL-23-Th17 pathway. J Exp Med. 2009; 206(8):1661-71. PMC: 2722164. DOI: 10.1084/jem.20090585. View

Hudson M, Pope J, Mahler M, Tatibouet S, Steele R, Baron M . Clinical significance of antibodies to Ro52/TRIM21 in systemic sclerosis. Arthritis Res Ther. 2012; 14(2):R50. PMC: 3446416. DOI: 10.1186/ar3763. View

Medsger Jr T, Bombardieri S, Czirjak L, Scorza R, Della Rossa A, Bencivelli W . Assessment of disease severity and prognosis. Clin Exp Rheumatol. 2003; 21(3 Suppl 29):S42-6. View

Decker P, Moulinet T, Lopez B, Dubucquoi S, Bonnotte B, Lakomy D . Clinical significance of anti-Ro52 (TRIM21) antibodies in adult patients with connective tissue diseases. Eur J Intern Med. 2021; 91:45-52. DOI: 10.1016/j.ejim.2021.04.020. View

Pakozdi A, Nihtyanova S, Moinzadeh P, Ong V, Black C, Denton C . Clinical and serological hallmarks of systemic sclerosis overlap syndromes. J Rheumatol. 2011; 38(11):2406-9. DOI: 10.3899/jrheum.101248. View

Lee A, Patterson K, Tan D, Wilson M, Proudman S, Stevens W . Anti-Ro52/TRIM21 is independently associated with pulmonary arterial hypertension and mortality in a cohort of systemic sclerosis patients. Scand J Rheumatol. 2021; 50(6):469-474. DOI: 10.1080/03009742.2021.1887927. View

Espinosa A, Hennig J, Ambrosi A, Anandapadmanaban M, Abelius M, Sheng Y . Anti-Ro52 autoantibodies from patients with Sjögren's syndrome inhibit the Ro52 E3 ligase activity by blocking the E3/E2 interface. J Biol Chem. 2011; 286(42):36478-91. PMC: 3196112. DOI: 10.1074/jbc.M111.241786. View

van den Hoogen F, Khanna D, Fransen J, Johnson S, Baron M, Tyndall A . 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum. 2013; 65(11):2737-47. PMC: 3930146. DOI: 10.1002/art.38098. View

10.

Sujau I, Ng C, Sthaneshwar P, Sockalingam S, Cheah T, Yahya F . Clinical and autoantibody profile in systemic sclerosis: baseline characteristics from a West Malaysian cohort. Int J Rheum Dis. 2014; 18(4):459-65. DOI: 10.1111/1756-185X.12322. View

11.

Wolin S, Reinisch K . The Ro 60 kDa autoantigen comes into focus: interpreting epitope mapping experiments on the basis of structure. Autoimmun Rev. 2006; 5(6):367-72. DOI: 10.1016/j.autrev.2005.10.004. View

12.

Vancsa A, Csipo I, Nemeth J, Devenyi K, Gergely L, Danko K . Characteristics of interstitial lung disease in SS-A positive/Jo-1 positive inflammatory myopathy patients. Rheumatol Int. 2009; 29(9):989-94. DOI: 10.1007/s00296-009-0884-9. View

13.

Espinosa A, Zhou W, Ek M, Hedlund M, Brauner S, Popovic K . The Sjogren's syndrome-associated autoantigen Ro52 is an E3 ligase that regulates proliferation and cell death. J Immunol. 2006; 176(10):6277-85. DOI: 10.4049/jimmunol.176.10.6277. View

14.

Higgs R, Lazzari E, Wynne C, Gabhann J, Espinosa A, Wahren-Herlenius M . Self protection from anti-viral responses--Ro52 promotes degradation of the transcription factor IRF7 downstream of the viral Toll-Like receptors. PLoS One. 2010; 5(7):e11776. PMC: 2909902. DOI: 10.1371/journal.pone.0011776. View

15.

Hoeper M, Bogaard H, Condliffe R, Frantz R, Khanna D, Kurzyna M . Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol. 2013; 62(25 Suppl):D42-50. DOI: 10.1016/j.jacc.2013.10.032. View

16.

La Corte R, Lo Mo Naco A, Locaputo A, Dolzani F, Trotta F . In patients with antisynthetase syndrome the occurrence of anti-Ro/SSA antibodies causes a more severe interstitial lung disease. Autoimmunity. 2006; 39(3):249-53. DOI: 10.1080/08916930600623791. View

17.

Yayla M, Ilgen U, Duzgun N . An analysis of the relationship between autoantibodies and clinical findings in patients with systemic sclerosis. Turk J Med Sci. 2018; 48(1):10-15. DOI: 10.3906/sag-1708-67. View

18.

Tsuboi H, Asashima H, Takai C, Hagiwara S, Hagiya C, Yokosawa M . Primary and secondary surveys on epidemiology of Sjögren's syndrome in Japan. Mod Rheumatol. 2013; 24(3):464-70. DOI: 10.3109/14397595.2013.843765. View

19.

Gunnarsson R, El-Hage F, Aalokken T, Reiseter S, Lund M, Garen T . Associations between anti-Ro52 antibodies and lung fibrosis in mixed connective tissue disease. Rheumatology (Oxford). 2015; 55(1):103-8. DOI: 10.1093/rheumatology/kev300. View

20.

Denton C, Khanna D . Systemic sclerosis. Lancet. 2017; 390(10103):1685-1699. DOI: 10.1016/S0140-6736(17)30933-9. View